Insider Sellers Might Regret Selling Biokarpet Shares at a Lower Price Than Current Market Value

Even though Biokarpet S.A. (ATH:BIOKA) has fallen by 11% over the past week , insiders who sold €1.3m worth of stock over the past year have had less luck. Insiders might have been better off holding onto their shares, given that the average selling price of €2.79 is still below the current share price.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

Check out our latest analysis for Biokarpet

The Last 12 Months Of Insider Transactions At Biokarpet

In the last twelve months, the biggest single sale by an insider was when the Chairman of the Board & CEO, Ioannis Kantonias, sold €452k worth of shares at a price of €2.74 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (€2.17). So it may not shed much light on insider confidence at current levels. Ioannis Kantonias was the only individual insider to sell shares in the last twelve months.

Ioannis Kantonias divested 463.00k shares over the last 12 months at an average price of €2.79. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

Insiders At Biokarpet Have Sold Stock Recently

The last quarter saw substantial insider selling of Biokarpet shares. Specifically, Chairman of the Board & CEO Ioannis Kantonias ditched €644k worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Biokarpet insiders own 40% of the company, worth about €21m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At Biokarpet Tell Us?

An insider sold Biokarpet shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 5 warning signs we've spotted with Biokarpet (including 1 which makes us a bit uncomfortable).

But note: Biokarpet may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com